ASX | Jotup

Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute

Retrieved on:

Monday, December 19, 2022

Clinical and Translational Science Award, Child, ASX, Research, Infection, FSE, AIR, City, RCE, Recce, Murdoch Children's Research Institute, Intellectual property, Pharmaceutical industry, Vaccine

SYDNEY, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children's). The agreement secures a dedicated research team of infectious disease experts and fit-for-purpose laboratory space with access to a library of clinical isolates and drug-resistant pathogens.

Key Points:

Subsidised collaborative for tackling infectious diseases – cost-efficient studies, laboratory space provided at no additional cost
SYDNEY, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children's).
“We are thrilled to enter this agreement with Murdoch Children's, as it will give Recce direct access to critical pre-clinical laboratory studies,” said Phil Sutton, Ph.D., Vice President of Translational Sciences of Recce Pharmaceuticals.
Murdoch Children’s Research Institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.
Based in Melbourne, one of the most innovative cities for world-leading medical research and development, the dedicated research within Recce’s AIR Unit will streamline ongoing pre-clinical programs and explore new research development opportunities.

European Lithium and Sizzle Acquisition Corp. Announce Filing of F-4 Registration Statement with the SEC

Retrieved on:

Friday, December 23, 2022

European Lithium Ltd (ASX: EUR) (“European Lithium”), announced today that it has filed a Form F-4 Registration Statement ("F-4") with the U.S. Securities and Exchange Commission ("SEC") regarding European Lithium’s recently announced business combination (the “Business Combination”) with Sizzle Acquisition Corp., (Nasdaq: SZZL) (“Sizzle”), a publicly traded special purpose acquisition company, to form Critical Metals Corp. (“Critical Metals”).

Key Points:

European Lithium Ltd (ASX: EUR) (“European Lithium”), announced today that it has filed a Form F-4 Registration Statement ("F-4") with the U.S. Securities and Exchange Commission ("SEC") regarding European Lithium’s recently announced business combination (the “Business Combination”) with Sizzle Acquisition Corp., (Nasdaq: SZZL) (“Sizzle”), a publicly traded special purpose acquisition company, to form Critical Metals Corp. (“Critical Metals”).
“We are pleased to reach this important step in our plans to list Critical Metals on Nasdaq,” said Critical Metals Executive Chairman, Tony Sage.
As agreed in the Business Combination, Critical Metals will own European Lithium’s Wolfsberg Lithium Project (the “Project”), which is currently owned by European Lithium’s wholly owned subsidiary, European Lithium AT (Investments) Limited, as well as a 20% interest in additional Austrian projects currently held by European Lithium.
European Lithium will be the largest shareholder of Critical Metals and is expected to continue to trade on the Australian Securities Exchange (“ASX”).

Critical Metals Corp. Announces Execution of Binding Lithium Offtake Agreement with BMW

Retrieved on:

Wednesday, December 21, 2022

European Lithium Ltd (ASX: EUR) (“European Lithium”), a mineral exploration company in a proposed business combination (the “Proposed Business Combination”) with Sizzle Acquisition Corp (Nasdaq: SZZL) (“Sizzle”) to form Critical Metals Corp. (“Critical Metals” or the “Company”), today announced that it has signed a binding long term lithium offtake agreement (the “Offtake Agreement”) via its wholly-owned Austrian subsidiary ECM Lithium AT GmbH (“ECM Lithium”) with auto manufacturer Bayerische Motoren Werkte Aktiengesellschaft (“BMW”).

Key Points:

European Lithium Ltd (ASX: EUR) (“European Lithium”), a mineral exploration company in a proposed business combination (the “Proposed Business Combination”) with Sizzle Acquisition Corp (Nasdaq: SZZL) (“Sizzle”) to form Critical Metals Corp. (“Critical Metals” or the “Company”), today announced that it has signed a binding long term lithium offtake agreement (the “Offtake Agreement”) via its wholly-owned Austrian subsidiary ECM Lithium AT GmbH (“ECM Lithium”) with auto manufacturer Bayerische Motoren Werkte Aktiengesellschaft (“BMW”).
The Offtake Agreement secures the Company’s first offtake of battery-grade lithium hydroxide to be sourced from the Wolfsberg Lithium Project (the “Project”) in Austria.
As part of the Offtake Agreement, BMW has been granted the first right to purchase 100% of the lithium hydroxide produced from the identified resources at the Project.
European Lithium will be the largest shareholder of Critical Metals and is expected to continue to trade on the Australian Securities Exchange.

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

Retrieved on:

Sunday, January 8, 2023

Growth, Prostate cancer, Conference, Kidney, TLX, US, ASX, Pharmaceutical industry, Telix

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).

Key Points:

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).
This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch.
Group CEO and Managing Director, Dr. Christian Behrenbruch stated, "We are very pleased with the continued sales momentum since launching Illuccix in the United States in April 2022.
The presentation will take place on Wednesday 11 January 2023 at 11.00am PST (Thursday 12 January 6.00am AEDT).

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

Retrieved on:

Sunday, January 8, 2023

Growth, Prostate cancer, Conference, Kidney, TLX, US, ASX, Pharmaceutical industry, Telix

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).

Key Points:

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).
This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch.
Group CEO and Managing Director, Dr. Christian Behrenbruch stated, "We are very pleased with the continued sales momentum since launching Illuccix in the United States in April 2022.
The presentation will take place on Wednesday 11 January 2023 at 11.00am PST (Thursday 12 January 6.00am AEDT).

Airspace Experience Technologies Announces Partnership with Mail Management Services

Retrieved on:

Friday, January 6, 2023

North American International Auto Show, Partnership, ASX, Research, MMS, CES, City, USPS, Airport, Carbon, Airline, Rail transport, Lincoln

DETROIT, Jan. 6, 2023 /PRNewswire/ -- In their latest partnership announcement, Airspace Experience Technologies (ASX) has signed an agreement with Mail Management Services out of Lincoln, Nebraska to supply eVTOLs to their fleet in 2025. This announcement was made at CES in Las Vegas on January 6th, 2023.

Key Points:

Founded and developed in Detroit, ASX and Mail Management Services, based in Lincoln, Nebraska
DETROIT, Jan. 6, 2023 /PRNewswire/ -- In their latest partnership announcement, Airspace Experience Technologies (ASX) has signed an agreement with Mail Management Services out of Lincoln, Nebraska to supply eVTOLs to their fleet in 2025.
MMS has partnered with Airspace Experience Technologies to deploy eVTOL aircraft to transport USPS payloads between cities, airports and suburbs.
Beginning in 2023, Mail Management Services will begin their journey towards fleet electrification with infrastructure projects at their owned facilities.
By elevating our vehicles above the roadways, we will dramatically enhance performance and reduce carbon emissions," said John Pool, COO of Mail Management Services.

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Retrieved on:

Tuesday, January 3, 2023

SAN, Drug discovery, Neuropsychiatry, Parkinson's disease, Disease, Movement disorders, ATH, Conference, Neurodegeneration, Multimedia, CNS, ASX, Therapy, Ophthalmology, Alterity, Pharmaceutical industry, Parkinsonism

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).

Key Points:

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).
The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.
At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders."
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.

CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology

Retrieved on:

Tuesday, January 3, 2023

IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.

Key Points:

The new partnership will allow ATCOR and Invaryant to jointly conduct clinical trials and research on maternal health and cardiovascular disease.
The "Pulse", a new device from CardieX subsidiary CONNEQT , will provide advanced arterial health metrics to users from the comfort of their own home.
CardieX's CONNEQT subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels.
Invaryant has woven patented security and interoperability technologies with first-of-its-kind AI, Inara, to intelligently support patients and their healthcare providers, making Invaryant the ideal platform for person-centric healthcare and clinical research.

Edge Impulse and BrainChip Partner to Further AI Development with Support for the Akida platform

Retrieved on:

Tuesday, January 3, 2023

SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Edge Impulse announced today official support for BrainChip's neural processor AI IP, making BrainChip the first strategic IP partner on the Edge Impulse platform.

Key Points:

SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Edge Impulse announced today official support for BrainChip's neural processor AI IP, making BrainChip the first strategic IP partner on the Edge Impulse platform.
Among the products supported by Edge Impulse is BrainChip's AKD1000 SoC, the first available device with Akida IP for developers.
The Akida IP platform provides low-power, high-performance edge AI acceleration, designed to enable real-time machine learning inferencing on-device.
Edge Impulse and BrainChip have an established relationship, previously announcing cross-platform support, including support for deploying Edge Impulse projects on the BrainChip MetaTF platform.

PointsBet Online and Mobile Sports Betting Now Live in Ohio

Retrieved on:

Sunday, January 1, 2023

ADW, Australian Securities Exchange, EST, NBA, PBH, NFL playoffs, Bet, The, Association football, MLB, Buckeye, ASX, Sport, NFL, New Year, College Football Playoff National Championship, Lightning

DENVER, Jan. 1, 2023 /PRNewswire/ -- PointsBet Holdings Limited (ASX: PBH), the leader in live betting, today announced the company has officially unveiled its market-leading mobile app and digital sports betting product in the state of Ohio.

Key Points:

Ohio bettors can ring in the New Year with PointsBet's LIGHTNING BETS™ for NFL, NBA, MLB, NCAAB, and Soccer
DENVER, Jan. 1, 2023 /PRNewswire/ -- PointsBet Holdings Limited (ASX: PBH), the leader in live betting, today announced the company has officially unveiled its market-leading mobile app and digital sports betting product in the state of Ohio.
"2023 is already proving to be a momentous year for PointsBet as today we have officially launched our mobile sports betting product in Ohio," said PointsBet USA CEO Johnny Aitken.
As part of its OddsFactory proprietary technology integration, PointsBet brings fans closer to the action with hundreds of live betting options across all sports.
PointsBet is the only operator in the market to offer Name A Bet, Live Same Game Parlays, and Pointsbetting.